TY - JOUR
T1 - Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma
AU - Karpetsky, Timothy P.
AU - Humphrey, Richard L.
AU - Levy, Carl C.
N1 - Funding Information:
ABBREVIATIONS USED: Cr = serum creatinine concentration; CCr = creatinine clearance; Poly C = polycytidylate; BSA = bovine serum albumin. 1 Received May 26, 1976; accepted September 27, 1976. 2 Supported in part by Public Health Service (PHS) grant CA06973 and PHS contract N01 CM43718 from the Division of Cancer Treatment, National Cancer Institute. 3 The Baltimore Cancer Research Center, National Cancer Institute, Baltimore, Md. 21211. 4 The Oncology Center, The Johns Hopkins University School of Medicine, The Baltimore City Hospitals, Baltimore, Md. 21224.
PY - 1977/4
Y1 - 1977/4
N2 - Serum RNase levels were measured in 34 patients with multiple myeloma and compared with 51 normal controls and 28 non-myeloma patients on chronic hemodialysis. Nineteen of the myeloma patients with creatinine clearance (Ccr) greater than 50 ml/minute had mean serum RNase levels that were statistically indistinguishable from those of the normal controls. The 15 myeloma patients with CCr less than 50 ml/minute had mean RNase levels much higher than normal controls or myeloma patients with normal renal function. Patients without myeloma but on hemodialysis for chronic renal failure of varied etiologies had markedly elevated serum RNase levels. A strong correlation between RNase levels and renal insufficiency, as measured by CCr, has thus been demonstrated. In addition, case histories of 5 representative myeloma patients were analyzed in greater detail; they illustrated the rise and fall of RNase levels as a function of the status of their renal insufficiency, regardless of the extent of the underlying myeloma. We concluded that the serum RNase level was an indicator of renal function, and was not a biomarker either for the presence or extent of the plasma cell tumor.
AB - Serum RNase levels were measured in 34 patients with multiple myeloma and compared with 51 normal controls and 28 non-myeloma patients on chronic hemodialysis. Nineteen of the myeloma patients with creatinine clearance (Ccr) greater than 50 ml/minute had mean serum RNase levels that were statistically indistinguishable from those of the normal controls. The 15 myeloma patients with CCr less than 50 ml/minute had mean RNase levels much higher than normal controls or myeloma patients with normal renal function. Patients without myeloma but on hemodialysis for chronic renal failure of varied etiologies had markedly elevated serum RNase levels. A strong correlation between RNase levels and renal insufficiency, as measured by CCr, has thus been demonstrated. In addition, case histories of 5 representative myeloma patients were analyzed in greater detail; they illustrated the rise and fall of RNase levels as a function of the status of their renal insufficiency, regardless of the extent of the underlying myeloma. We concluded that the serum RNase level was an indicator of renal function, and was not a biomarker either for the presence or extent of the plasma cell tumor.
UR - http://www.scopus.com/inward/record.url?scp=0017576809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017576809&partnerID=8YFLogxK
U2 - 10.1093/jnci/58.4.875
DO - 10.1093/jnci/58.4.875
M3 - Article
C2 - 845991
AN - SCOPUS:0017576809
SN - 0027-8874
VL - 58
SP - 875
EP - 880
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 4
ER -